posted on 2023-03-31, 20:26authored byMichael T. Tetzlaff, Jonathan L. Curry, Jing Ning, Oded Sagiv, Thomas L. Kandl, Bo Peng, Diana Bell, Mark Routbort, Courtney W. Hudgens, Doina Ivan, Tae-Boom Kim, Ken Chen, Agda Karina Eterovic, Kenna Shaw, Victor G. Prieto, Anna Yemelyanova, Bita Esmaeli
Supplementary Table 1. Summary of mutations identified in the entire cohort of primary, locally recurrent and metastatic tumors.
Funding
Avery Orbital Oncology Fund for Research and Education
History
ARTICLE ABSTRACT
Ocular adnexal (OA) sebaceous carcinoma is an aggressive malignancy of the eyelid and ocular adnexa that frequently recurs and metastasizes, and effective therapies beyond surgical excision are lacking. There remains a critical need to define the molecular-genetic drivers of the disease to understand carcinomagenesis and progression and to devise novel treatment strategies.
We present next-generation sequencing of a targeted panel of cancer-associated genes in 42 and whole transcriptome RNA sequencing from eight OA sebaceous carcinomas from 29 patients.
We delineate two potentially distinct molecular-genetic subtypes of OA sebaceous carcinoma. The first is defined by somatic mutations impacting TP53 and/or RB1 [20/29 (70%) patients, including 10 patients whose primary tumors contained coexisting TP53 and RB1 mutations] with frequent concomitant mutations affecting NOTCH genes. These tumors arise in older patients and show frequent local recurrence. The second subtype [9/29 (31%) patients] lacks mutations affecting TP53, RB1, or NOTCH family members, but in 44% (4/9) of these tumors, RNA sequencing and in situ hybridization studies confirm transcriptionally active high-risk human papillomavirus. These tumors arise in younger patients and have not shown local recurrence.
Together, our findings establish a potential molecular-genetic framework by which to understand the development and progression of OA sebaceous carcinoma and provide key molecular-genetic insights to direct the design of novel therapeutic interventions.